NCT01804166View on ClinicalTrials.gov

A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)

PHASE4CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 21, 2013

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
Hepatosplenic T-Cell Lymphoma
Interventions
DRUG

Infliximab

This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.

DRUG

Golimumab

This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.

Trial Locations (1)

Unknown

Norfolk

All Listed Sponsors
lead

Janssen Scientific Affairs, LLC

INDUSTRY

NCT01804166 - A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | Biotech Hunter | Biotech Hunter